Severe congenital neutropenia (SCN) is a genetically heterogenous, rare disorder defined by a persistent absolute neutrophil count <500k mm À3 with neutrophil maturation arrest at the promyelocyte stage and an increased risk for infection as well as a propensity towards developing myelodysplastic syndrome and acute myelogenous leukemia. We report a case of incidentally identified SCN in a full-term, otherwise healthy infant girl. Routine complete blood counts obtained for follow up of ABO incompatibility-induced jaundice and anemia identified mild neutropenia at birth followed by severe persistent neutropenia by 1 week of birth. Genetic testing confirmed the clinical suspicion of SCN with the identification of a mutation in the ELANE gene. Prompt identification and treatment of infants with SCN is critical to minimizing morbidity and mortality; as such, a diagnosis of SCN must be considered in all infants with neutropenia even in the absence of infection.
Introduction
Severe congenital neutropenia (SCN) is a rare disease entity with a prevalence of two cases per million people. 1, 2 Clinically, SCN is characterized by a paucity of peripherally circulating neutrophils with arrest of neutrophil maturation at the promyelocyte stage and consequent increased susceptibility to severe and recurrent infections. Besides increased infection risk, patients with SCN treated with granulocyte colony stimulating factor (G-CSF) also have an underlying predisposition to myelodysplastic syndrome/ acute myelogenous leukemia revealed with increasing age. 3 Although the first description of the disease in 1956 by the Swedish pediatrician, Rolf Kostmann, detailed the autosomal recessive form of SCN most commonly because of HAX1 mutations, 4 it is now recognized that SCN is a genetically heterogenous disorder with multiple modes of inheritance including autosomal recessive (accounting for B30% of patients), autosomal dominant (accounting for B60% of patients), X-linked and sporadic. 5 Mutations associated with SCN have been identified in HAX1, ELANE (previously ELA2), GFI1, WAS, CSF3R and G6PC3. 6, 7 Regardless of the mode of inheritance or specific mutation, newborns with SCN have severe neutropenia, defined as an absolute neutrophil count (ANC) <500 k mm À3 , often appreciable at birth or shortly thereafter. 1, 8 Frequent episodes of fever, skin infections, gingivitis, stomatitis, pneumonia and perirectal abscesses are common in the first few months of life and before the advent of G-CSF therapy death from overwhelming serious infection was common by 1 year of age. 8 Prompt diagnosis of SCN in infancy and initiation of treatment to prevent infection is crucial to decreasing morbidity and mortality. Care must also be taken to monitor for the development of myelodysplasia and leukemia transformation.
Case
Our patient presented in infancy with incidentally recognized neutropenia. She was born full term to a health gravida 1 para 1 mother after an uneventful pregnancy, but her neonatal course was complicated by anemia and jaundice from ABO incompatibility requiring phototherapy and subsequent monitoring of her blood counts. At birth, her white blood cell count was 7400 k mm À3 with an ANC of 1110 k mm
À3
. After 1 week, however, her white blood cell count was 8100 k mm À3 with an ANC of 405 k mm À3 . Sepsis evaluation was negative. A diagnosis of alloimmune neutropenia was considered, but anti-neutrophil antibodies were negative. 9 Furthermore, she had multiple repeat blood counts obtained over a 8 week period that revealed a persistently low ANC ranging from 0 to 1110 k mm À3 with the majority of the ANC values below 200 k mm À3 , concerning for congenital neutropenia. She was asymptomatic with no fever, mouth sores, gingivitis, vaginal sores, folliculitis or other infections. Family history did not identify anyone with cytopenias, death from overwhelming infection in childhood nor any consanguineous unions. Her evaluation culminated in a bone marrow aspirate obtained at 3 months of age that demonstrated neutrophil arrest at the promyelocyte stage and an increase in eosinophil precursors consistent with a diagnosis of congenital neutropenia. Cytogenetics from the bone marrow sample were normal, that is, 46 XX. Confirmation of the diagnosis of congenital neutropenia was obtained through gene mutation analysis for ELANE that revealed a heterozygous P110L mutation in exon 4 of the ELANE gene previously reported as a recognized cause of congenital neutropenia. 10 The patient was started on filgastrim 7.5 mcg kg À1 daily, titrated to maintain her ANC between 1000 and 2000 k mm À3 , to minimize her risk of infection. At 11 months of age she has had no serious infections to date. Discussion ELANE mutations are associated with the autosomal dominant and sporadically inherited forms of SCN. 10 Mutations in the ELANE gene are the most frequently identified genetic basis for SCN with 35-63% of SCN patients found to have a mutation in the neutrophil elastase gene. [11] [12] [13] Thus, all patients with suspected SCN are recommended to have ELANE genotyping performed. 13 Those patients identified to have an ELANE mutation do not require further testing. Patients with negative ELANE testing should undergo further gene testing as dictated by their clinical and family history.
Treatment of SCN focuses on the prevention of infection. Recombinant human G-CSF has been the mainstay of treatment since its introduction in 1987 and is considered the standard of care for preventing life-threatening bacterial sepsis. 14, 15 For patients who do not respond to G-CSF, or who develop myelodysplastic syndrome/leukemia, stem cell transplantation is the only alternative treatment. 16, 17 SCN is recognized as a pre-leukemic condition with B20% of patients developing leukemia. 3 Leukemic transformation has been noted in both the autosomal recessive 18 and dominant 11 subtypes of SCN. The majority of leukemic transformation results in acute myelogenous leukemia.
The Severe Chronic Neutropenia International Registry is now gathering data on those ELANE mutations that appear to predispose to leukemic transformation. Our patient thus far has a mutation, which appears not to be associated with leukemic transformation. 19 Because of the risk of myelodysplasia and leukemic predisposition; however, a yearly bone marrow is recommended for patients, including our patient, with SCN to monitor for morphological and cytogenetic changes as well as the development of G-CSF receptor mutations that may herald the development of leukemic transformation. 16 Our patient will also have quarterly complete blood counts to monitor the risk for malignant changes.
